{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.372","value":"13.67"},{"groupId":"OG001","spread":"32.309","value":"30.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Clinical serum chemistry tests included total protein. Change from baseline in clinical serum chemistry tests i.e. total protein at Day 100 were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of tinostamustine 180 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG000","title":"Tinostamustine 180 mg/m^2"},{"description":"Participants received single dose of tinostamustine 220 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG001","title":"Tinostamustine 220 mg/m^2"}],"paramType":"MEAN","populationDescription":"Safety population included all participants who received tinostamustine. The study was early terminated on 17 April 2019, due to safety signals during Phase 1, participants were not enrolled in Phase 2.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -1), Day 100","title":"Phase 1 and 2: Change From Baseline in Clinical Serum Chemistry Tests: Total Protein","type":"SECONDARY","unitOfMeasure":"gram per liter (g/L)"}